key: cord-0735161-d428a1ij
authors: Kaakati, Rayan; Khokhar, Dilawar; Akin, Cem
title: Safety of COVID-19 Vaccination in Patients with Mastocytosis and Monoclonal Mast Cell Activation Syndrome
date: 2021-05-24
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.05.010
sha: b60135a0033bad329aba8b0a41d39722663cfff1
doc_id: 735161
cord_uid: d428a1ij

nan

(1). Eliciting factors of anaphylaxis include venom stings, drugs, and food (2). There is limited data on the tolerance of vaccinations in patients with mastocytosis with prior work 48 predominantly focusing on children with mastocytosis who were shown to have a higher rate of 49 adverse reactions to first administration of vaccine than that of the general population (3). The 50 COVID-19 pandemic has led to the development of multiple vaccines, but early rollout of these 51 vaccines has been plagued by reports of allergic reactions including anaphylaxis (4). This has led 52 to concern about whether patients with a propensity for anaphylaxis (such as patients with 53 mastocytosis) can safely tolerate COVID-19 vaccines (5,6), and an NIH sponsored multicenter 54 trial to examine this question (7). We present a series of 18 patients with a history of 55 mastocytosis that underwent COVID-19 vaccination (full series).

We performed a retrospective chart review of 259 patients with a diagnosis of cutaneous Table 1 . Demographic characteristics of our cohort J o u r n a l P r e -p r o o f Types of Vaccine Administered Pfizer Moderna Janssen

Anaphylaxis in patients with mastocytosis: a study on 136 history, clinical features and risk factors in 120 patients

Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin 139 North Am

Evaluation of 142 vaccination safety in children with mastocytosis

Response Team; Food and Drug Administration

Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

MMWR Morb Mortal Wkly Rep

mRNA COVID-19 vaccine is well tolerated in patients with 151 cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are 155

mRNA Vaccines Safe in Mast Cell Disorders?